|
Delayed
London S.E.
03:52:31 2026-09-25 EDT
|
5-day change | 1st Jan Change | ||
| 90.00 GBX | +1.69% |
|
+4.65% | +11.80% |
| 08-13 | EARNINGS AND TRADING: tinybuild sues Max Ent; Light Science loss grows | AN |
| 08-13 | Arecor Therapeutics plc Publishes Clinical Data for AT278 in Peer-Reviewed Journal | CI |
Projected Income Statement: Arecor Therapeutics plc
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 1.158 | 2.403 | 4.573 | 5.053 | 3.163 | 0.8785 | 1.05 |
| Change | - | 107.51% | 90.3% | 10.5% | -37.4% | -72.23% | 19.52% |
| EBITDA 1 | -6.268 | -10.29 | -8.679 | -6.963 | -3.506 | -5.729 | -4.172 |
| Change | - | -64.15% | 15.65% | 19.77% | 49.65% | -63.39% | 27.18% |
| EBIT 1 | -6.439 | -10.63 | -9.175 | -7.409 | 0.667 | -6.2 | -4.474 |
| Change | - | -65.09% | 13.69% | 19.25% | 109% | -1,029.49% | 27.84% |
| Interest Paid | -0.507 | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -6.945 | -10.54 | -8.901 | -10.62 | 0.726 | -5.789 | -4.432 |
| Change | - | -51.79% | 15.57% | -19.29% | 106.84% | -897.35% | 23.44% |
| Net income | -6.169 | -9.26 | -8.554 | -10.24 | - | - | - |
| Change | - | -50.11% | 7.62% | -19.66% | - | - | - |
| Announcement Date | 4/25/22 | 4/20/23 | 5/16/24 | 4/22/25 | 4/13/26 | - | - |
1GBP in Million
Estimates
Forecast Balance Sheet: Arecor Therapeutics plc
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Net Debt 1 | -18.3 | -12.8 | -6.75 | -3.26 | -6.03 | -1.32 | 3.2 |
| Change | - | 30.05% | 47.27% | 51.7% | -84.97% | 78.12% | 342.42% |
| Announcement Date | 4/25/22 | 4/20/23 | 5/16/24 | 4/22/25 | 4/13/26 | - | - |
1GBP in Million
Estimates
Cash Flow Forecast: Arecor Therapeutics plc
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| CAPEX 1 | 0.069 | 0.299 | 0.151 | 0.023 | - | - | - |
| Change | - | 333.33% | -49.5% | -84.77% | - | - | - |
| Free Cash Flow (FCF) 1 | - | -11.08 | -5.992 | -9.178 | -2.462 | -4.661 | -1.198 |
| Change | - | - | 45.92% | -53.17% | 73.17% | -89.32% | 74.3% |
| Announcement Date | 4/25/22 | 4/20/23 | 5/16/24 | 4/22/25 | 4/13/26 | - | - |
1GBP in Million
Estimates
Forecast Financial Ratios: Arecor Therapeutics plc
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||
| EBITDA Margin (%) | - | -541.28% | -428.17% | -189.79% | -137.8% | -110.84% | -652.09% | -397.3% |
| EBIT Margin (%) | - | -556.04% | -442.36% | -200.63% | -146.63% | 21.09% | -705.72% | -426.08% |
| EBT Margin (%) | - | -599.74% | -438.7% | -194.64% | -210.13% | 22.95% | -658.94% | -422.09% |
| Net margin (%) | - | -532.73% | -385.35% | -187.05% | -202.57% | - | - | - |
| FCF margin (%) | - | - | -461.05% | -131.03% | -181.63% | -77.84% | -530.56% | -114.08% |
| FCF / Net Income (%) | - | - | 119.64% | 70.05% | 89.66% | - | - | - |
Profitability | ||||||||
| ROA | -49.89% | -29.64% | -30.63% | -30.88% | -38.43% | -30.06% | - | - |
| ROE | -138.25% | -63.85% | -51.44% | -63.41% | -137.62% | 15.79% | - | - |
Financial Health | ||||||||
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | -0.77x |
| Debt / Free cash flow | - | - | - | - | - | - | - | -2.67x |
Capital Intensity | ||||||||
| CAPEX / Current Assets (%) | - | 5.96% | 12.44% | 3.3% | 0.46% | - | - | - |
| CAPEX / EBITDA (%) | - | -1.1% | -2.91% | -1.74% | -0.33% | - | - | - |
| CAPEX / FCF (%) | - | - | -2.7% | -2.52% | -0.25% | - | - | - |
Items per share | ||||||||
| Cash flow per share 1 | - | -0.2366 | -0.3725 | -0.1907 | - | - | - | - |
| Change | - | - | -57.44% | 48.81% | - | - | - | - |
| Dividend per Share 1 | - | - | - | - | - | - | - | - |
| Change | - | - | - | - | - | - | - | - |
| Book Value Per Share 1 | - | - | 0.5701 | 0.3111 | 0.1746 | 0.1636 | 0.0154 | - |
| Change | - | - | - | -45.43% | -43.88% | -6.27% | -90.6% | - |
| EPS 1 | - | -0.27 | -0.32 | -0.28 | -0.31 | - | - | - |
| Change | - | - | -18.52% | 12.5% | -10.71% | - | - | - |
| Nbr of stocks (in thousands) | - | 27,835 | 30,618 | 30,627 | 37,757 | 37,757 | 37,757 | 37,757 |
| Announcement Date | - | 4/25/22 | 4/20/23 | 5/16/24 | 4/22/25 | 4/13/26 | - | - |
1GBP
Estimates
| 2026 * | 2027 * | |
|---|---|---|
| P/E | - | - |
| PBR | 57.5x | - |
| EV / Sales | 36.5x | 34.9x |
| Yield | - | - |
EPS & Dividend
Y-o-Y evolution of P/E
Year-on-year evolution of the Yield
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.8850GBP
Average target price
2.755GBP
Spread / Average Target
+211.30%
Annual profits - Rate of surprise
- Stock Market
- Stocks
- AREC Stock
- Financials Arecor Therapeutics plc
Select your edition
All financial news and data tailored to specific country editions
